Read by QxMD icon Read

Antibody rejection

Tetsuo Koshizuka, Yasushi Matsuda, Hirotoshi Suzuki, Ryoko Kanno, Kazufumi Ikuta, Takahiro Kobayashi, Takashi Kondo, Yoshinori Okada, Tatsuo Suzutani
Transplant recipients become immunocompromised through the use of immunosuppressive therapy to prevent allograft rejection. These recipients readily experience human cytomegalovirus (CMV) infection or reactivation. Therefore, CMV represents a life-threatening pathogen in transplant recipients. To demonstrate the serostatus and course of IgG maturation against CMV in transplant patients, we measured the transition of anti-CMV IgG and its affinity (avidity index; AI) as criteria for antibody maturation. Among 31 lung transplant recipients, 26 were infected with CMV before transplantation and maintained anti-CMV IgG and high AI values throughout the study period...
December 12, 2018: Transplant Immunology
Manabu Okada, Yoshihiko Watarai, Kenta Iwasaki, Kenta Futamura, Takayuki Yamamoto, Takahisa Hiramitsu, Makoto Tsujita, Norihiko Goto, Shunji Narumi, Asami Takeda, Takaaki Kobayashi
Recently, in vitro experiments have demonstrated that anti-blood group A/B antibody binding to endothelial cells induce a protective effect against antibody-mediated injury. This study aimed to clarify the potential clinical benefit of ABO incompatibility in donor-specific HLA antibody (DSA)-induced chronic antibody-mediated rejection (ABMR). We enrolled 215 ABO-incompatible renal transplant (ABO-I) and 467 ABO-identical/compatible renal transplant recipients (ABO-Id/C). The prevalence of de novo DSA production and incidence of biopsy-proven chronic ABMR were compared between the two groups...
December 12, 2018: Human Immunology
C Randall Harrell, Bojana Simovic Markovic, Crissy Fellabaum, Aleksandar Arsenijevic, Vladislav Volarevic
Osteoarthritis (OA) is a chronic, prevalent, debilitating joint disease characterized by progressive cartilage degradation, subchondral bone remodeling, bone marrow lesions, meniscal damage, and synovitis. Innate immune cells (natural killer cells, macrophages, and mast cells) play the most important pathogenic role in the early inflammatory response, while cells of adaptive immunity (CD4 + Th1 lymphocytes and antibody producing B cells) significantly contribute to the development of chronic, relapsing course of inflammation in OA patients...
January 2019: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Ines G Harper, Olivera Gjorgjimajkoska, Jacqueline Hy Siu, Jasvir Parmar, Arend Mulder, Frans Hj Claas, Sarah A Hosgood, Michael L Nicholson, Reza Motallebzadeh, Gavin J Pettigrew
Tissue resident lymphocytes are present within many organs, and are presumably transferred at transplantation, but their impact upon host immunity is unclear. Here we examine whether transferred donor natural regulatory CD4 T cells (nT-regs) inhibit host alloimmunity and prolong allograft survival. Transfer of donor-strain lymphocytes was first assessed by identifying circulating donor-derived CD4 T cells in 21 consecutive human lung transplant recipients, with three patterns of chimerism apparent: transient; intermediate; and persistent (detectable for up to 6 weeks, 6 months, and beyond one year, respectively)...
December 12, 2018: American Journal of Transplantation
Diana Llopiz, Marta Ruiz, Lorea Villanueva, Tamara Iglesias, Leyre Silva, Josune Egea, Juan J Lasarte, Perrine Pivette, Véronique Trochon-Joseph, Bérangère Vasseur, Graham Dixon, Bruno Sangro, Pablo Sarobe
Immune checkpoint inhibitors are currently tested in different combinations in patients with advanced hepatocellular carcinoma (HCC). Nivolumab, an anti-PD-1 agent, has gained approval in the second-line setting in the USA. Epigenetic drugs have immune-mediated antitumor effects that may improve the activity of immunotherapy agents. Our aim was to study the therapeutic efficacy of checkpoint inhibitors (anti-CTLA-4 and anti-PD-1 antibodies) in combination with the histone deacetylase inhibitor (HDACi) Belinostat...
December 13, 2018: Cancer Immunology, Immunotherapy: CII
Peng Guo, Yun Wang, Zhichao Chen, Tianqi Jin, Li Fu, Cheng-Te Lin, Guosong Lai
The authors describe a nanocomposite that was obtained by in-situ deposition of CdS nanocrystals on mesoporous silica nanospheres (MSNs), and its use in an electrochemical immunoassay of human immunoglobulin G (HIgG). The MCN/CdS nanocomposite was covalently modified with the antibodies against HIgG and then employed in a voltammetric immunoassay at antibody-functionalized magnetic beads. Through sandwich immunoreaction, the MCN/CdS nanoprobes are quantitatively captured onto the magnetic beads where numerous Cd(II) ions are released in an acidic solution...
December 12, 2018: Mikrochimica Acta
Ibai Los-Arcos, Oscar Len, Manel Perello, Irina B Torres, Gemma Codina, Juliana Esperalba, Joana Sellarés, Francesc Moreso, Daniel Seron, Joan Gavaldà
BACKGROUND: Data are scarce on cytomegalovirus (CMV) and BK virus (BKV) infection after antibody-mediated rejection (ABMR). OBJECTIVES: We hypothesized that the immunological response in patients with ABMR or the immune modulation associated with its treatment could predispose to CMV and BKV infection. Our objective was to investigate this hypothesis. STUDY DESIGN: We conducted a single-center, matched case-control study (1:2 ratio) to analyze CMV and BKV replication during the first year after the ABMR diagnosis in kidney transplant recipients...
December 1, 2018: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
Y Lv, X Pang, P-Y Jia, D-L Jia
OBJECTIVE: Indoleamine 2, 3-dioxygenase (IDO) can inhibit rejection of graft via inducing T cell apoptosis. CD40L monoclonal antibody (mAb) inhibits T cell activation. However, the effects of the combination of infusion of dendritic cell (DC) from IDO over-expressed donor mice and CD40L mAb on the treatment of graft rejection after heart transplantation have not been reported. MATERIALS AND METHODS: Allogeneic heart transplantation mouse model was established. Recipient mice were divided into three groups, including control group, IDO group (in which DC donors received adenoviral vector of IDO) and combined therapy group (which received both IDO over-expressed DC infusion and CD40L mAb injection post transplantation)...
November 2018: European Review for Medical and Pharmacological Sciences
Grecia M Marrón-Liñares, Lucía Núñez, Manuel Hermida-Prieto
No abstract text is available yet for this article.
November 9, 2018: Oncotarget
Branislav Kollar, Bohdan Pomahac, Leonardo V Riella
PURPOSE OF REVIEW: Vascularized composite allotransplantation (VCA) is a promising approach to restore the quality of life of carefully selected patients that suffered extensive injury. Although acute rejection occurs very frequently, still little is known about the specific characteristics of the VCA immune response. This review aims to highlight the current development in the field of VCA concerning the immunobiology and management of upper extremity and face transplant recipients. RECENT FINDINGS: T-cell mediated rejection is the predominant mechanism of allograft injury in VCA...
December 6, 2018: Current Opinion in Organ Transplantation
Pauline Erpicum, Laurent Weekers, Olivier Detry, Catherine Bonvoisin, Marie-Hélène Delbouille, Céline Grégoire, Etienne Baudoux, Alexandra Briquet, Chantal Lechanteur, Gianni Maggipinto, Joan Somja, Hans Pottel, Frédéric Baron, François Jouret, Yves Beguin
Mesenchymal stromal cells (MSCs) exhibit anti-inflammatory and immune-regulatory properties, and preclinical studies suggest a potential benefit in solid organ transplantation. We report on the 1-year follow-up of an open-label phase I-II trial of a single infusion of third-party MSC post-kidney transplantation, in addition to standard immunosuppression. Ten kidney transplant recipients from deceased donors received third-party bone marrow MSCs (∼2 × 106 /kg) on day 3 ± 2 post-transplant and were compared to 10 concurrent controls...
December 6, 2018: Kidney International
Aws Almufleh, Habibat Garuba, Lisa M Mielniczuk, Ross A Davies, Ellamae Stadnick, Eric Belanger, Alexander Dick, Stella Kozuszko, Heather J Ross, Sharon Chih
Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging has prognostic utility in populations with cardiac disease, including heart transplant (HT) recipients. The etiology of specific LGE patterns and their correlation with outcomes after HT are unclear. Antibody-mediated rejection and cardiac allograft vasculopathy are major causes of death, and their evaluation remains challenging. We report identical diffuse subepicardial LGE in 2 highly allosensitized HT recipients who developed allograft failure...
December 2018: Canadian Journal of Cardiology
Wouter W H Kopp, Claar C A T van Leeuwen, David H D Lam, Volkert V A L Huurman, Hans J W de Fijter, Sandro A F Schaapherder, Andre A G Baranski, Andries A E Braat
INTRODUCTION: Complete graft thrombosis is the leading cause of early graft loss following pancreas transplantation. Partial thrombosis is usually subclinical and discovered on routine imaging. Treatment options may vary in such cases. We describe the incidence and relevance of partial graft thrombosis in a large transplant center. METHODS: All consecutive pancreas transplantation at our center (2004-2015) were included in this study. Radiological follow-up, type and quantity of thrombosis prophylaxis, complications and graft and patient survival were collected...
December 7, 2018: Transplant International: Official Journal of the European Society for Organ Transplantation
C-E Hsieh, Y Yang, K-H Lin, C-C Chen, C-J Ko, Y-L Hsu, C-C Lin, Y-J Hung, P-Y Lin, S-H Wang, Y-L Chen
We present a patient with positive donor-specific antibodies (DSA) and crossmatch of ABO-incompatible (ABOi) combined liver and kidney transplantation (CLKT). Antibody-mediated rejection did not occur and the graft had survived for over one year at the time of writing without infectious complications. A 56-year-old man with positive DSA and positive crossmatch underwent living donor CLKT. The preoperative protocol for ABOi consisted of a single dose of rituximab and total plasma exchange (TPE). The result of anti-B antibody titer for IgG was 1:32...
May 29, 2018: Transplantation Proceedings
Guoqiang Zhang, Hidetaka Hara, Takayuki Yamamoto, Qi Li, Abhijit Jagdale, Yong Li, David K C Cooper, Hayato Iwase
BACKGROUND: There is well-documented systemic inflammatory response in xenograft recipients to the presence of a pig graft. Serum amyloid A (SAA) is an inflammatory marker that is elevated in various pathological states. The assay used to measure it is (i) simple, (ii) relatively inexpensive, and (iii) provides an answer within minutes. METHOD: The levels of SAA (n = 11) and C-reactive protein (C-RP) (n = 8) were measured retrospectively in the serum of baboons with pig kidney transplants, who received therapy with an IL-6R inhibitor and a TNF-α antagonist...
December 3, 2018: International Journal of Surgery
Marieke van der Zwan, Dennis A Hesselink, Marian C Clahsen-van Groningen, Carla C Baan
BACKGROUND: There is an unmet need for reliable minimally invasive diagnostic biomarkers for immunological allograft monitoring and for the detection of acute kidney transplant rejection. Here, targeted proteomic analysis was applied to compare 92 proteins in sera of belatacept-treated patients who had biopsy-proven, acute T cell-mediated rejection (aTCMR) with patients without aTCMR. METHODS: Proximity extension immunoassay (PEA) was used to measure 92 inflammation-related protein concentrations in the pre-rejection and rejection sera of 11 patients with aTCMR and 9 patients without aTCMR...
December 4, 2018: Therapeutic Drug Monitoring
Fabiani Palagi Machado, Alessandra Rosa Vicari, Fábio Spuldaro, João Batista Saldanha de Castro Filho, Roberto Ceratti Manfro
OBJECTIVE: To investigate the correlation between total lymphocyte and CD3+ T cell counts in peripheral blood in renal transplant patients treated with anti-thymocyte globulin, and discuss related outcomes. METHODS: A single-center, retrospective study involving 226 patients submitted to kidney transplant between 2008 and 2013, and treated with anti-thymocyte globulin for induction or treatment of cellular rejection. Doses were adjusted according to CD3+ T cell or total lymphocyte counts in peripheral blood...
November 29, 2018: Einstein
Chiu-Yu Chen, Paul Warner, Erin L Albers, Mariska S Kemna, Meghan Delaney, Borah J Hong, Yuk M Law
ABO-i heart transplantation can be performed in infants with end-stage heart failure to increase organ availability. The development of newly detected DSAs is associated with decreased cardiac graft survival, and the effect of ABO-i transplantation on DSA production is unknown. We examined DSA production and rejection frequency in infant recipients of ABO-i and ABO-c heart transplants via a retrospective cohort study of infant heart transplant recipients transplanted at a single pediatric center between January 2004 and November 2014...
December 4, 2018: Pediatric Transplantation
Flavie Ngo Nyekel, Emeline Pacreau, Samira Benadda, Rasha Msallam, Magnus Åbrink, Gunnar Pejler, Jean Davoust, Marc Benhamou, Nicolas Charles, Pierre Launay, Ulrich Blank, Gregory Gautier
Recent evidences indicate an important role of tissue inflammatory responses by innate immune cells in allograft acceptance and survival. Here we investigated the role of mast cells (MC) in an acute male to female skin allograft rejection model using red MC and basophil (RMB) mice enabling conditional MC depletion. Kinetic analysis showed that MCs markedly accelerate skin rejection. They induced an early inflammatory response through degranulation and boosted local synthesis of KC, MIP-2, and TNF. This enhanced early neutrophil infiltration compared to a female-female graft-associated repair response...
2018: Frontiers in Immunology
Jesmar Buttigieg, Hatem Ali, Ajay Sharma, Ahmed Halawa
The presence of pre-formed donor-specific antibodies (DSAs) in kidney transplantation is associated with worse overall outcomes compared with DSA-negative transplantation. A positive complement-dependant cytotoxic crossmatch presents a high immunological risk, while a negative flow cytometry crossmatch is at the lower end of the risk spectrum. Yet, the presence of low-level DSA detected by Luminex alone, that is, positive Luminex and negative flow (PLNF) cytometry crossmatch lacks robust scientific exploration...
November 30, 2018: Nephrology, Dialysis, Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"